GBT Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 Okt 2022 @ 22:00):

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD)...

Stats
Tagesvolumen	3.28M
Durchschnittsvolumen	0
Marktkapitalisierung	0.00
EPS	$0 ( 2022-11-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.08
ATR14	$0.890 (1.30%)

Insider Trading

Date	Person	Action	Amount	type
2022-10-05	Perry Mark L	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Patrick Deval L	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Morrison Scott W	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Thompson Alexis A.	Sell	3 600	Restricted Stock Units
2022-10-05	Yarno Wendy L	Sell	30 000	Stock Option (Right to Buy)

INSIDER POWER
-60.35
Last 100 transactions
Buy: 278 284 \| Sell: 1 075 911

Volumen Korrelation

Lang: 0.35 (neutral)

Kurz: 0.93 (very strong)

Signal:(77.112) Expect same movement, but be aware

Global Blood Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Global Blood Korrelation - Währung/Rohstoff

0.94
( very strong )

0.92
( very strong )

-0.79
( moderate negative )

0.83
( strong )

0.23
( neutral )

-0.61
( weak negative )

Global Blood Finanzdaten

Annual	2021
Umsatz:	$194.75M
Bruttogewinn:	$191.43M (98.30 %)
EPS:	$-4.82

FY	2021
Umsatz:	$194.75M
Bruttogewinn:	$191.43M (98.30 %)
EPS:	$-4.82

FY	2020
Umsatz:	$123.80M
Bruttogewinn:	$121.82M (98.40 %)
EPS:	$-4.04

FY	2019
Umsatz:	$2.11M
Bruttogewinn:	$2.06M (97.72 %)
EPS:	$-4.57

Financial Reports:

No articles found.

Global Blood

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.